Investor Relations

Stock Quote - Ticker Tape

 

SEC Filings

  o View CEL-SCI's SEC Filings  
       

Warrant Quote

  o NYSE MKT: CVM WS  

 

Press Releases

  o Press Releases  
  DECEMBER 8, 2014
NEW STORY CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with Addition of 7 More Clinical Sites
  DECEMBER 2, 2014
NEW STORY CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period
  OCTOBER 24, 2014
NEW STORY CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million
  OCTOBER 21, 2014
NEW STORY CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering
  SEPTEMBER 29, 2014
NEW STORY CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients
  AUGUST 8, 2014
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results
  JULY 30, 2014
France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial
  JULY 15, 2014
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment
 

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com